IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations
selected using molecular diagnostics. The company\'s product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California. The company trades on NASDAQ exchange. The company headquarter is located in South San Francisco, CA. The company was established in the 2015.
| Ticker | IDYA |
| Long Name | Ideaya Biosciences, Inc. |
| Short Name | Ideaya Biosciences |